4 - Profusa, Inc. (0001859807) (Issuer)

4 - Profusa, Inc. (0001859807) (Issuer)

4 - Profusa, Inc. (0001859807) (Issuer)

4 - Profusa, Inc. (0001859807) (Issuer)

4 - Profusa, Inc. (0001859807) (Issuer)

4 - Profusa, Inc. (0001859807) (Issuer)

4 - Profusa, Inc. (0001859807) (Issuer)

4 - Profusa, Inc. (0001859807) (Issuer)

4 - Profusa, Inc. (0001859807) (Issuer)

4 - Profusa, Inc. (0001859807) (Issuer)

BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) --  Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a  digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces  that, effective May 15, 2026, the Company will now be listed on The Nasdaq Capital Market.  The move is the first of a previously announced series of interim milestones as laid out by the Nasdaq Hearings Panel to ensure continued compliance with the bid price and stockholders' equity requirements for continued listing on the Capital Market tier. About ProfusaBased in Berkeley, CA, Profusa is a commercial stage digital health co

WEST PALM BEACH, Fla, May 14, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a company assembling an AI-powered System-of-Systems autonomous defense platform spanning drone warfare, counter-UAS, demining, and command-and-control applications, today announced the appointment of Peter M. O'Rourke Sr. as an independent member of its Board of Directors, effective immediately. Mr. O'Rourke served as Acting Secretary of the U.S. Department of Veterans Affairs (VA) under the Trump administration in 2018, where he led over 380,000 employees and helped oversee one of the largest federal healthcare and benefits systems in the country, with an annual bu

BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a  digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announced that, by letter dated May 6, 2026, the Nasdaq Hearings Panel granted the Company's request to transfer the listing of its securities from The Nasdaq Global Market to The Nasdaq Capital Market. The Company's continued listing on Nasdaq is subject to the Company's satisfaction of certain interim milestones and, ultimately, the Company's compliance with the bid price and stockholders' equity requirements for continued listing on the

Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to enhance scale, strengthen execution and support long-term shareholder value creation BERKELEY, CA, May 05, 2026 (GLOBE NEWSWIRE) --  Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a digital health company pioneering next-generation biosensing technologies, today announced that its Board of Directors has initiated a Board-led process to evaluate strategic alternatives intended to maximize shareholder value and support the Company's highest-priority commercial, regulatory and platform-e

Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, today announced a strategic expansion into molecular diagnostics through a Letter of Intent to acquire the PanOmics™ multi-omics diagnostics platform from BioInsights LLC ("BioInsights").  The Company believes this acquisition, a

After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term Revenue Projections BERKELEY, CA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has elected not to proceed with its public offering and intends to file a post-effective amendment with the U.S. Securities and Exchange Commission (the "SEC") for the Company's

With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million - $3 million BERKELEY, Calif, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has received several purchase orders for the Lumee™ tissue oxygen monitoring system from its growing network of European distributors and expert physician customers.  With strong underlying market

Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to enable the continuous monitoring of an individual's biochemistry, has entered into a know-how agreement with Mayo Clinic.  The collaboration entails investigation of high impact clinical applicatio

BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-seventy-five (1:75) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on February 9, 2026, and the Company's common stock will open for trading on The Nasdaq Global Market on February 9, 2026 on a

Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces the presentation of positive US-study clinical trial results at Leipzig Interventional Course in Leipgzig, Germany on Wednesday, January 28, 2026.  The study, conducted at the University of California San Francisco, San Francisco VA Medical Center, and San Francisco General Hospital, showed Lumee oxygen tissue monitoring is a

DEF 14A - Profusa, Inc. (0001859807) (Filer)

8-K - Profusa, Inc. (0001859807) (Filer)

424B3 - Profusa, Inc. (0001859807) (Filer)

8-K - Profusa, Inc. (0001859807) (Filer)

10-Q - Profusa, Inc. (0001859807) (Filer)

8-K - Profusa, Inc. (0001859807) (Filer)

PRE 14A - Profusa, Inc. (0001859807) (Filer)

8-K - Profusa, Inc. (0001859807) (Filer)

EFFECT - Profusa, Inc. (0001859807) (Filer)

424B3 - Profusa, Inc. (0001859807) (Filer)